A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Abrocitinib (Primary) ; Dabigatran etexilate
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 19 Dec 2018 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
- 30 Nov 2018 Planned End Date changed from 12 Feb 2019 to 1 Mar 2019.